FDA Watch: FDA Approves Enhanced Cologuard Cancer Test
Test maker Exact Sciences says it expects Cologuard Plus to cut false positives by more than 30 percent
Keeps You Up-to-Date on Federal & State Laws, Regulations, New Legislation, and Court Cases that Affect Your Diagnostic Lab or Pathology Practice
Test maker Exact Sciences says it expects Cologuard Plus to cut false positives by more than 30 percent
What happens when a whistleblower’s case is based on information that’s already been publicly disclosed?
CMS recently announced some important changes affecting PAMA price reporting, along with a list of 17 new PLA codes that will be recognized.
The US Food and Drug Administration recently issued a letter warning people not to use two different tests produced by Empowered Diagnostics.
The cost of recoveries hit an eight-year high in FY 2021, with the health care industry footing 90 percent of the bill.
Here’s a look at the key takeaways from the Dec. 30 OIG report on Medicare Part B spending on lab testing.
Labs that bill federal health care programs for these tests need to pay especially close attention to ensure compliance.